Cart
sales@molnova.com
RIPK1-IN-9
CAS No. 2682889-57-0
RIPK1-IN-9( —— )
Catalog No. M35690 CAS No. 2682889-57-0
RIPK1-IN-9 is a potent and selective inhibitor of RIPK1, a dihydronaphthone compound, which inhibits U937 and L929 cells with an IC50 of 2 nM and 1.3 nM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 547 | Get Quote |
|
| 5MG | 823 | Get Quote |
|
| 10MG | 1131 | Get Quote |
|
| 25MG | 1628 | Get Quote |
|
| 50MG | 2190 | Get Quote |
|
| 100MG | 2898 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameRIPK1-IN-9
-
NoteResearch use only, not for human use.
-
Brief DescriptionRIPK1-IN-9 is a potent and selective inhibitor of RIPK1, a dihydronaphthone compound, which inhibits U937 and L929 cells with an IC50 of 2 nM and 1.3 nM, respectively.
-
DescriptionRIPK1-IN-9 (example 45), a dihydronaphthyridone compound, is a potent and selective RIPK1 inhibitor. RIPK1-IN-9 inhibits U937 cell (IC50=2 nM) and L929 cell (IC50=1.3 nM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetRIP kinase
-
RecptorRIP kinase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2682889-57-0
-
Formula Weight472.51
-
Molecular FormulaC26H25FN6O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C=2C(=NC=C(C2)C3=CC=4N(C=C3)N=C(N)N4)CCN1CC5=C(OC6CCCC6)C=CC(F)=C5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Fusheng Zhou, et al. Dihydronaphthyridone compounds, their preparation and pharmaceutical uses. WO2021160109A1.
molnova catalog
related products
-
Necrostatin 2 racema...
Necrostatin 2 racemate is an potent and specific inhibitor of?RIPK1.
-
GSK-481
A highly potent, monokinase selective and ATP-competitive inhibitor of RIP1 kinase with biochemical IC50 of 10 nM.
-
Necrostatin-34
Necrostatin-34 is a RIPK1 kinase inhibitor, stabilizing RIPK1 kinase in an inactive conformation by occupying a distinct binding pocket in the kinase domain.
